Nanoviricides (NNVC) Receivables - Other (2014)

Nanoviricides (NNVC) posted Receivables - Other of $4.5 million for Q2 2014.

Nanoviricides (NNVC) Receivables - Other (2014) Analysis & Trends

Nanoviricides has reported Receivables - Other for 1 years, with the latest figure at $4.5 million in Q2 2014.

Quarterly Receivables - Other changed N/A year-over-year to $4.5 million in Q2 2014, while the trailing twelve-month figure through Jun 2014 was $4.5 million (changed N/A YoY) and the FY2014 annual result came in at $4.5 million, changed N/A from the prior year.
Receivables - Other was little changed at $4.5 million in Q2 2014 per NNVC's latest filing.
Over five years, Receivables - Other peaked at $4.5 million in Q2 2014 and troughed at $4.5 million in Q2 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.71 Bn	131.86 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.55 Bn	78.55 Bn	3.93 Bn
3	Argenx Se	65.26 Bn	60.07 Bn	1.37 Bn
4	Moderna	59.81 Bn	54.67 Bn	52.00 Mn
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.87 Bn	28.56 Bn	992.69 Mn
7	BioNTech SE	28.13 Bn	9.74 Bn	668.28 Mn
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn
9	Royalty Pharma	27.31 Bn	26.47 Bn	-
10	Nanoviricides	29.50 Mn	26.28 Mn	-

Download Data

Date	Value
Jun 30, 2014	4.50 Mn
Jun 30, 2014	4.50 Mn